Health
FDA authorizes marketing of new device for short-term treatment of gait deficit in MS patients – News-Medical.Net
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate…
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that consists of a non-implantable apparatus…
-
Business23 hours agoThe ASX 200 returned 13.4% in FY25. Here’s how you could have got a slice
-
Noosa News22 hours agoFormer Brisbane Lions sponsor goes bust, leaving 200 workers in limbo
-
Noosa News22 hours agoHero rescuer reveals terrifying details of horror shark attack at Cabarita Beach in NSW
-
General22 hours agoSouth Australia Premier Peter Malinauskas under fire over awarding of golf course redesign contract to Greg Norman